Axcelis Technologies, Inc. logo

Axcelis Technologies, Inc.

ACLS

NASDAQTechnologySemiconductors

Previous close

$127.07

+$2.10 · +1.68%

Aug 21, 4:00 PM ET

ACLS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

66

Undervalued

Momentum

40

Weakening

Sentiment

47

Mixed

Risk resilience

41

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Axcelis Technologies, Inc. is a company dedicated to the creation, production, and maintenance of specialized ion implantation and other essential processing machinery used in the fabrication of semiconductor chips. Operating internationally, its presence extends across North America, Europe, and Asia. The firm offers a wide array of implanter technologies, such as high-energy, high-current, and medium-current systems, designed to meet diverse application needs. Furthermore, Axcelis provides extensive post-sales support and lifecycle solutions, including the sale of pre-owned equipment, replacement parts, system upgrades, ongoing maintenance, and client instruction. It directly furnishes its advanced equipment and services to microchip manufacturers through its own dedicated sales personnel. Founded in 1978, Axcelis Technologies has its corporate headquarters situated in Beverly, Massachusetts.

Industry
Semiconductors
Sector
Technology
Headquarters
US
CEO
Russell J. Low
Listed since
Jul 11, 2000
Employees
1,465

Market position

Day range

Current $127.07

52-week range

Current $127.07

Open
$123.99
Previous close
$124.97
Volume
378.91K
0.63× average
Average volume
600.09K
Average daily volume
Market cap
3.91B USD
Beta
1.88
Market reference 1
50-day average
$147.76
-14.00% below average
200-day average
$115
+10.49% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.43B USD
P/E (TTM)
42.36×
P/B (TTM)
3.67×
P/S (TTM)
4.51×
EV / EBITDA
15.09×
Earnings yield
4.74%
Free cash flow yield
4.22%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
43.01%
Operating margin
10.33%
Net margin
10.71%
Return on equity
11.62%
Return on assets
8.83%
Return on invested capital
8.91%

Financial health

Debt / equity
0.04×
Current ratio
4.77×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends48%36%23%11%Gross margin, FY2021: 43.24%Gross margin, FY2022: 43.67%Gross margin, FY2023: 43.45%Gross margin, FY2024: 44.67%Gross margin, FY2025: 44.91%Operating margin, FY2021: 19.22%Operating margin, FY2022: 23.08%Operating margin, FY2023: 23.51%Operating margin, FY2024: 20.71%Operating margin, FY2025: 14.22%Net margin, FY2021: 14.89%Net margin, FY2022: 19.90%Net margin, FY2023: 21.78%Net margin, FY2024: 19.75%Net margin, FY2025: 14.33%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 43.24%. Gross margin FY2022 43.67%. Gross margin FY2023 43.45%. Gross margin FY2024 44.67%. Gross margin FY2025 44.91%. Operating margin FY2021 19.22%. Operating margin FY2022 23.08%. Operating margin FY2023 23.51%. Operating margin FY2024 20.71%. Operating margin FY2025 14.22%. Net margin FY2021 14.89%. Net margin FY2022 19.90%. Net margin FY2023 21.78%. Net margin FY2024 19.75%. Net margin FY2025 14.33%.

Income trends

Revenue

839.05M USD-17.57%

Operating income

119.32M USD-43.40%

Net income

120.24M USD-40.18%
Income trends across reported periods1.23B USD821.02M USD408.24M USD−4.55M USDRevenue, FY2021: 662.43M USDRevenue, FY2022: 920M USDRevenue, FY2023: 1.13B USDRevenue, FY2024: 1.02B USDRevenue, FY2025: 839.05M USDOperating income, FY2021: 127.33M USDOperating income, FY2022: 212.36M USDOperating income, FY2023: 265.8M USDOperating income, FY2024: 210.79M USDOperating income, FY2025: 119.32M USDNet income, FY2021: 98.65M USDNet income, FY2022: 183.08M USDNet income, FY2023: 246.26M USDNet income, FY2024: 200.99M USDNet income, FY2025: 120.24M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 662.43M USD. Revenue FY2022 920M USD. Revenue FY2023 1.13B USD. Revenue FY2024 1.02B USD. Revenue FY2025 839.05M USD. Operating income FY2021 127.33M USD. Operating income FY2022 212.36M USD. Operating income FY2023 265.8M USD. Operating income FY2024 210.79M USD. Operating income FY2025 119.32M USD. Net income FY2021 98.65M USD. Net income FY2022 183.08M USD. Net income FY2023 246.26M USD. Net income FY2024 200.99M USD. Net income FY2025 120.24M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue839.05M USD1.02B USD1.13B USD920M USD662.43M USD
Cost of goods sold462.2M USD563.21M USD639.3M USD518.21M USD375.98M USD
Gross profit376.85M USD454.65M USD491.3M USD401.79M USD286.45M USD
Research and development108.96M USD105.5M USD96.91M USD78.36M USD65.43M USD
Selling, general, and administrative148.58M USD138.36M USD128.6M USD111.07M USD93.69M USD
Operating expenses257.53M USD243.86M USD225.51M USD189.43M USD159.12M USD
Interest income21.48M USD24.4M USD18.2M USD4.55M USD209K USD
Interest expense5.36M USD5.46M USD5.35M USD5.58M USD4.84M USD
Depreciation and amortization17.61M USD15.81M USD13.07M USD11.61M USD10.82M USD
Operating income119.32M USD210.79M USD265.8M USD212.36M USD127.33M USD
Net income120.24M USD200.99M USD246.26M USD183.08M USD98.65M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+33.44%
11 comparable reports
Latest EPS result
1.06
Estimate 0.89 · Beat by 18.57%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.631.20.770.33Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 10, 2025: actual 1.54, estimate 1.25, surprise +23.20%, Beat. Q2 2025, reported May 6, 2025: actual 1.04, estimate 0.39, surprise +166.67%, Beat. Q3 2025, reported Aug 5, 2025: actual 1.13, estimate 0.73, surprise +54.79%, Beat. Q4 2025, reported Nov 4, 2025: actual 1.21, estimate 1.01, surprise +19.80%, Beat. Q1 2026, reported Feb 17, 2026: actual 1.49, estimate 1.12, surprise +33.04%, Beat. Q2 2026, reported May 7, 2026: actual 0.72, estimate 0.71, surprise +1.41%, Beat. Q3 2026, reported Aug 6, 2026: actual 1.06, estimate 0.894, surprise +18.57%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 1.11, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates262.51M234.72M206.93M179.14MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 10, 2025: actual 252.42M USD, estimate 221.59M USD, surprise +13.91%, Beat. Q2 2025, reported May 6, 2025: actual 192.56M USD, estimate 189.23M USD, surprise +1.76%, Beat. Q3 2025, reported Aug 5, 2025: actual 194.54M USD, estimate 197.62M USD, surprise -1.56%, Miss. Q4 2025, reported Nov 4, 2025: actual 213.61M USD, estimate 215.04M USD, surprise -0.66%, Miss. Q1 2026, reported Feb 17, 2026: actual 238.33M USD, estimate 215.05M USD, surprise +10.83%, Beat. Q2 2026, reported May 7, 2026: actual 198.96M USD, estimate 195.03M USD, surprise +2.01%, Beat. Q3 2026, reported Aug 6, 2026: actual 215.18M USD, estimate 205.03M USD, surprise +4.95%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 230.08M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

13 ratings
Strong buy00%
Buy1077%
Hold215%
Sell18%
Strong sell00%

Recent analyst actions

8 institutions
The Benchmark CompanyupgradeHoldBuy
William BlairdowngradeOutperformMarket Perform
NeedhammaintainHold

ACLS news

Corporate actions

Corporate action history

Stock split

Effective Jul 1, 2016

1:4

ACLS peers

ETFs holding ACLS

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ACLS

research.disclaimer